Lack of Benefit for Liraglutide in Heart Failure

JAMA - Journal of the American Medical Association

Volumn 316, Issue 22, 2016, Pages 2429-

  Carbone, Salvatore ^a   Arena, Ross ^b   Abbate, Antonio ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; GLYCOSYLATED HEMOGLOBIN; LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1;

BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS; FUNCTIONAL STATUS; GLYCEMIC CONTROL; HEART DEATH; HEART FAILURE; HEART INFARCTION; HOSPITAL READMISSION; HUMAN; LETTER; OBESITY; PRIORITY JOURNAL; PROGNOSIS; WEIGHT REDUCTION; DIABETES MELLITUS, TYPE 2;

DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE;

EID: 85007524559     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2016.15387     Document Type: Letter

References (4)

1. Margulies KB, Hernandez AF, Redfield MM, et al; NHLBI Heart Failure Clinical Research Network. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial. JAMA. 2016;316(5):500-508.
2. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322.
3. Lepore JJ, Olson E, Demopoulos L, et al. Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC Heart Fail. 2016;4(7):559-566.
4. Rossignol P, Masson S, Barlera S, et al; GISSI-HF and Val-HeFT Investigators. Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials. Eur J Heart Fail. 2015;17(4):424-433.